Precision Treatment to Promote Smoking Cessation and Survival in Oncology Patients
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-89
SponsorWashington University School of Medicine
About this trial
This study evaluates the feasibility and preliminary effects of precision tobacco treatment, compared to usual care, on promoting tobacco treatment in oncology patients and providers in the oncology care setting. The precision treatment intervention includes personalized tobacco treatment recommendations using the patient's clinical, genetic, and biomarker information. This intervention may increase patient receipt of tobacco treatment, patient medication use, and patient smoking abstinence at 6 months.
Eligibility criteria
Qualifiers
Clinician from participating oncology/hematology clinic
At least 18 years of age
Can speak and understand English
Patient at participating clinic
Disqualifiers
Active use of smoking cessation medication (within the past 30 days)
Receipt of smoking cessation medication or prescription for smoking cessation medication (within the past 30 days)
Having a contradiction for cNRT or varenicline (allergic reactions, current cardiac problems, pregnancy)
Patients who were deemed by the investigator to be ineligible for participation in the trial
Trial design
Treatments tested in this trial
- Usual care
- Precision treatment
Treatment groups
112 Participants
are divided into 2 treatment groupsSponsors and collaborators
Washington University School of Medicine
Lead sponsor
United States Department of Defense
Collaborator
Source ClinicalTrials.gov